ABSTRACT
The development of an anti-radiation vaccine could be very useful in reducing acute radiation syndromes. Existing principles for the treatment of acute radiation syndromes are based on the amelioration of progressive pathophysiological changes, using the concept of replacement therapy. Active immunization by small quantities of the essential radiation-induced systemic toxins of what we call the Specific Radiation Determinant (SRD) before irradiation increased duration of life among animals that were irradiated by lethal or sub-lethal doses of gamma-radiation. The SRD toxins possess antigenic properties that are specific to different forms of acute radiation sickness. Intramuscular injection of larger quantities of the SRD toxins induce signs and symptoms in irradiated naive animals similar to those observed in acute radiation syndromes, including death. Providing passive immunization, at variable periods of time following radiation, with preparations of immune-globulins directed at the SRD molecules, can confer some protection in the development of clinical sequelae in irradiated animals. Improved survival rates and times were observed in animals that received lower, sublethal doses of the same SRDs prior to irradiation. Therefore, active immunization can be induced by SRD molecules as a prophylaxis. The protective effects of the immunization begin to manifest 15-35 days after an injection of a biologically active SDR preparation. The SRD molecules are a group of radiation toxins with antigenic properties that correlate specifically with different forms of radiation disease. The SRD molecules are composed of glycoproteins and lipoproteins that accumulate in the lymphatic system of mammals in the first hours after irradiation, and preliminary analysis suggests that they may originate from cellular membrane components. The molecular weight of the SRD group ranges from 200-250 kDa. The SRD molecules were isolated from the lymphatic systems of laboratory animals that were irradiated with doses known to induce the development of cerebral (SRD-1), non-specific toxic effects (SRD-2), gastrointestinal (SRD-3) and hematological (bone marrow) (SRD-4) syndromes. Our results suggest that an anti-radiation vaccine can be developed for prophylactic use against radiation damage induced by acute exposure to significant doses of low Linear Energy Transfer (LET) radiation for humans, including nuclear power workers, commercial and military pilots, cosmonauts/astronauts, nuclear-powered engine vessel operators and possibly even the civilian population in the case of a nuclear terrorism event.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Gamma Rays , Immunotherapy, Active/methods , Linear Energy Transfer , Radiation Injuries, Experimental/prevention & control , Radiation-Protective Agents/therapeutic use , Acute Disease , Adjuvants, Immunologic/isolation & purification , Animals , Antigens/immunology , Cattle , Dogs , Dose-Response Relationship, Radiation , Horses , Lymph Nodes/chemistry , Lymph Nodes/immunology , Mice , Rabbits , Radiation Dosage , Radiation Injuries, Experimental/immunology , Radiation-Protective Agents/isolation & purification , Rats , Sheep , SwineABSTRACT
Ovarian carcinoma multicellular spheroids are an in vitro model of micrometastasis whose adhesive abilities have not been elucidated. In this study, we identified adhesion molecules that mediate the formation of ovarian carcinoma spheroids and their subsequent adhesion to extracellular matrix proteins. The NIH:OVCAR5, but not the SKOV3, ovarian carcinoma cell line formed spheroids similar to multicellular aggregates isolated from patient ascitic fluid. NIH:OVCAR5 spheroid formation was augmented by a beta 1-integrin-stimulating monoclonal antibody or exogenous fibronectin, but was inhibited by blocking monoclonal antibodies against the alpha 5- or beta 1-integrin subunits. By immunohistochemical staining, alpha 2-, alpha 3-, alpha 5-, alpha 6-, and beta 1-integrin subunits, CD44, and fibronectin were detected in NIH:OVCAR5 spheroids. NIH:OVCAR5 spheroids adhered to fibronectin, laminin, and type IV collagen, and this adhesion was partially inhibited by blocking antibodies against the alpha 5-, alpha 6-, and alpha 2-integrin subunits, respectively. A blocking monoclonal antibody against the beta 1-integrin subunit completely inhibited adhesion of the spheroids to all three proteins. These results suggest that interactions between the alpha 5 beta 1-integrin and fibronectin mediate the formation of ovarian carcinoma spheroids and that their adhesion to extracellular matrix proteins at sites of secondary tumor growth may be mediated by a complex interaction between multiple integrins and their ligands.
Subject(s)
Cell Adhesion/physiology , Integrin beta1/physiology , Ovarian Neoplasms/physiopathology , Spheroids, Cellular/pathology , Antigens, CD/physiology , Cell Adhesion Molecules/analysis , Cell Division/physiology , Collagen Type IV/metabolism , Extracellular Matrix Proteins/metabolism , Female , Fibronectins/metabolism , Humans , Immunohistochemistry , Integrin alpha5 , Laminin/metabolism , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Protein Binding , Spheroids, Cellular/chemistry , Time Factors , Tumor Cells, CulturedABSTRACT
Epithelial cancer of the ovary spreads by implantation of tumor cells onto the mesothelial cells that line the peritoneal cavity. The aim of this study was to identify the cell-matrix interactions that mediate ovarian carcinoma cell migration toward components of the mesothelial cell-associated extracellular matrix. The human ovarian carcinoma cell lines NIH:OVCAR5 and SKOV3 were analyzed by flow cytometry for the expression of cell surface receptors. The ability of those receptors to mediate ovarian carcinoma cell migration toward fibronectin, type IV collagen, and laminin was determined. A monoclonal antibody against the beta1 integrin subunit abrogated the migration of both cell lines toward the extracellular matrix proteins. Blocking antibodies against alpha integrin subunits suggest that ovarian carcinoma cell migration toward fibronectin is primarily mediated by the alpha5beta1 integrin, type IV collagen by the alpha2beta1 integrin, and laminin by the alpha6beta1 integrin. These results suggest that ovarian carcinoma cell migration is regulated by multiple beta1 integrin-matrix interactions. Significant reduction of cell migration was observed with a monoclonal antibody against CD44 that blocks the hyaluronan-binding site of CD44, but not with an antibody that binds at an alternate site on CD44. Intact hyaluronan and/or hyaluronan oligomers also inhibited cell migration, suggesting that the CD44-hyaluronan interaction provides an integrin-independent mechanism of control for ovarian carcinoma cell migration. These results suggest that ovarian carcinoma cell migration is regulated by both integrin-dependent mechanisms, involving the interaction of beta1 integrins with extracellular matrix proteins, and an integrin-independent mechanism that involves the interaction of CD44 and hyaluronan.
Subject(s)
Cell Movement/physiology , Extracellular Matrix Proteins/physiology , Hyaluronan Receptors/physiology , Integrin beta1/physiology , Ovarian Neoplasms/pathology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Female , Humans , Hyaluronan Receptors/immunology , Integrin beta1/immunology , Tumor Cells, CulturedABSTRACT
Although progressive retinal neovascularization is a potentially blinding complication of several diseases, there are no good animal models. The authors developed a consistent model of preretinal neovascularization in the rabbit by partially digesting the posterior vitreous with repeated injection and aspiration of 1 IU of hyaluronidase before injection of 250,000 homologous dermal fibroblasts. The evolution of the new preretinal vessels was monitored by indirect ophthalmoscopy, fundus photography, and fluorescein angiography. A grading system was devised using fundus photographs and fluorescein angiograms to describe the progression of new vessel growth and the extent of fluorescein leakage. Ninety-five percent of the eyes had vascular enlargement and hyperemia but no fluorescein leakage by day 1. Fifteen percent of the eyes had clinically evident new preretinal vessels, and 32% had severe fluorescein leakage by day 7. Ninety-five percent of the eyes had definite neovascularization by day 14. Severe fluorescein leakage peaked at day 14 (55% of the eyes) and decreased thereafter. Involution or atrophy of the vessels occurred in all eyes by day 42. This model will be useful for studying the pathogenesis of preretinal neovascularization and evaluating potential treatments for its prevention.
Subject(s)
Disease Models, Animal , Retinal Neovascularization , Animals , Cells, Cultured , Fibroblasts/transplantation , Fluorescein Angiography , Hyaluronoglucosaminidase , Rabbits , Retinal Neovascularization/etiology , Retinal Neovascularization/pathology , Retinal Vessels/metabolism , Vitreous BodyABSTRACT
Soil samples from Cape Canaveral were subjected to a simulated Martian environment and assayed periodically over 45 days to determine the effect of various environmental parameters on bacterial populations. The simulated environment was based on the most recent available data, prior to the Viking spacecraft, describing Martian conditions and consisted of a pressure of 7 millibars, an atmosphere of 99.9% CO2 and 0.1% O2, a freeze-thaw cycle of -65 degrees C for 16 h and 24 degrees C for 8 h, and variable moisture and nutrients. Reduced pressure had a significant effect, reducing growth under these conditions. Slight variations in gaseous composition of the simulated atmosphere had negligible effect on growth. The freeze-thaw cycle did not inhibit growth but did result in a slower rate of decline after growth had occurred. Dry samples exhibited no change during the 45-day experiment, indicating that the simulated Martian environment was not toxic to bacterial populations. Psychotrophic organisms responded more favorably to this environment than mesophiles, although both types exhibited increases of approximately 3 logs in 7 to 14 days when moisture and nutrients were available.